MedTrace Logo

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

NCT00004409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.

Conditions

  • Dupuytren's Contracture

Interventions

DRUG

collagenase

Sponsors & Collaborators

  • State University of New York

    lead OTHER

Principal Investigators

  • Lawrence C. Hurst · State University of New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-08-31
Completion
2004-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004409 on ClinicalTrials.gov